Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
1998-10-01
2001-02-13
Fay, Zohreh (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S054000
Reexamination Certificate
active
06187745
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to methods and pharmaceutical compositions used to prevent kidney toxicity caused by cyclosporin or tacrolimus administration.
2. Description of the Prior Art
Cyclosporins are neutral, lipophilic, cyclic undecapeptides with molecular weights of about 1200. They are used intravenously or orally as immunosuppressants to prolong survival in allogenic transplants involving skin, bone marrow, heart, kidney, pancreas and other organs as well as in the treatment of autoimmune diseases.
One of the principal categories of adverse reactions experienced with cyclosporin therapy is renal dysfunction and toxicity, which creates limitations on the clinical applications of cyclosporins. Indeed, in spite of improved one- and two-year renal allograft survival rates, the average half-life of eight years for a cadaver kidney transplant that is functioning at one year has changed little with the use of cyclosporin-based immunosuppression during the past over 15 years. The adverse effects of cyclosporins, particularly the most commonly used cyclosporin, cyclosporin A (CyA) on long-term kidney structure and function have not been excluded as an important factor in chronic allograft failure syndrome. See Bennett et al.,
Kidney Intl
. , 50:1089-1100 (1996).
It has been established that CyA causes a dose-related decrease in renal function in experimental animals and humans which is thought to be due to the drug's effects in producing afferent arteriolar vasoconstriction and, ultimately, decreased glomerular filtration rate. However, these acute hemodynamic effects, which should be largely controllable with precise monitoring and dosing of patients, are apparently not the only adverse consequences of CyA administration for the kidney. Not only patients given CyA therapy to prevent organ transplant rejection, but also patients with autoimmune diseases, have been shown to develop morphologic lesions consisting of areas of striped tubulointerstitial fibrosis, tubular atrophy and afferent arteriolopathy. The hallmark of CyA nephropathy are these vascular lesions, which are not necessarily dose-related and which can be observed in some patients receiving CyA doses as low as 2 to 4 mg/kg. See Bennett et al., ibid.; Pankewycz et al.,
Kidney Intl.
, 50:1634-1640 (1996).
No effective technique has been disclosed in the prior art for the chronic administration of CyA and other cyclosporins at therapeutic doses while avoiding the serious consequences of nephrotoxicity. It has been suggested that calcium antagonists may modify the metabolism of CyA, allowing the use of lower doses to achieve adequate immunosuppression. It has also been proposed that dihydropyridine calcium channel blockers may slow interstitial fibrosis in kidney transplant recipients without affecting cyclosporin metabolism. The benefit of these proposed therapies has not been established, however, and there may be adverse effects caused by the chronic administration of calcium antagonists or calcium channel blockers that would outweigh their utility as adjunctive agents to cyclosporins even if they were effective in avoiding kidney damage.
SUMMARY OF THE INVENTION
It is the object of the present invention to provide a method of preventing or substantially reducing the nephrotoxicity caused by the administration of cyclosporins to mammalian patients.
It is another object of the present invention to provide a method as aforesaid which not only halts the disease process but actually reverses that process and causes regression of the scarring lesions.
It is a further object of the invention to provide a method as aforesaid which enables the administration of relatively high, therapeutically effective doses of cyclosporins to patients requiring cyclosporin therapy while avoiding cyclosporin nephrotoxicity and nephropathy.
It is yet another object of the present invention to provide a method as aforesaid utilizing a commercially available pharmaceutical agent which is non-toxic and not likely to provoke serious side effects.
In keeping with these objects and others which will become apparent hereinafter, the invention resides, briefly stated, in a method of preventing, reducing or reversing cyclosporin-induced nephrotoxicity and renal dysfunction in mammalian patients receiving cyclosporin therapy consisting of the administration to such patients of an effective nephrotoxicity-reducing amount of pentosan polysulfate (PPS) or a pharmaceutically acceptable salt thereof. Oral administration of PPS is the preferred mode of administration.
In another aspect, the present invention resides in a method of treating mammalian patients requiring immunosuppressive therapy to prevent allograft rejection or to treat autoimmune diseases through the concomitant administration of an effective immunosuppression-inducing amount of a cyclosporin and an effective nephrotoxicity-reducing amount of PPS of a pharmaceutically acceptable salt thereof. Alternatively, the effective amount of PPS may be administered concomitantly with FK-506 (Fujisawa), also known as tacrolimus, which is used to provide immunosuppression in organ transplant patients, particularly in cases of liver transplants.
REFERENCES:
patent: 5204329 (1993-04-01), Akerman et al.
patent: 5605938 (1997-02-01), Roufa et al.
patent: 5643892 (1997-07-01), Striker et al.
patent: 0 466 315 A2 (1992-01-01), None
Bennett et al.,Kid Int., vol. 50, pp. 1089-1100 (1996).
Debnam et al.,Kid. Int., vol. 50, pp. 1101-1109 (1996).
Andoh et al.,Kid Int., vol. 50, pp. 1110-1117 (1996).
Pankewycz et al.,Kid Int., vol. 50, pp. 1634-1640 (1996).
Peten,J. Am. Soc. Neph., vol. 41, p. 780, 111p (1993).
Floege et al.,Kid. Int., vol. 43, pp. 369-380 (1993).
Naparstek et al.,Arth.&Rheum., vol. 33, No. 10, pp. 1554-1559 (1990).
Wardle,J. Int. Med. Res., vol. 20, pp. 361-370 (1992).
Nethery et al.,Biochem. Pharm., vol. 44, No. 8, pp. 1549-1553 (1992).
Striker et al., Lab. Inv., vol. 64, No. 4., pp. 446-456 (1991).
Pesce et al.,Lab. Inv., vol. 65, No. 5, pp. 601-605 (1991).
Wilke et al.,Cleveland Clin. J. Med., pp. 753-754 (Nov./Dec. 1989).
Purkerson et al.,J. Clin. Invest., vol. 81, pp. 69-74 (1988).
Herbert et al.,Artery, vol. 16, No. 1, pp. 1-14 (1988).
Adler,Am. J. Physiol., vol. 255, pp. F781-F786 (1988).
Herbert et al.,Biochem. Pharm., vol. 37, No. 22, pp. 4281-4288 (1988).
Andrews,Chem. Bio. Interactions, vol. 41, p. 780, 111p (1993).
Fye et al.,Arch Intern. Med., vol. 136, pp. 995-999 (1976).
Bone et al.,Kid Int., vol. 8, pp. 72-79 (1975).
Zimmerman et al.,Nephron, vol. 12, pp. 219-230 (1974).
Arieff et al.,Arch. Intern. Med., vol. 129, pp. 77-84 (1972).
Freedman et al.,Inv. Urol., vol. 7, No. 5, pp. 398-409 (1970).
Kincaid-Smith et al.,The Lancet, pp. 1360-1364 (1968).
SP54 Package Insert for pentosanpolysulphate sodium, Bene Arzneimittel GmbH.
Kortright Kenneth H.
Striker Gary E.
Striker Liliane J.
Baker Norton Pharmaceuticals, Inc.
Fay Zohreh
Kirschstein et al.
LandOfFree
Method of preventing nephrotoxicity caused by cyclosporins... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of preventing nephrotoxicity caused by cyclosporins..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of preventing nephrotoxicity caused by cyclosporins... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2606796